The creation of Enectarol opens the door to a new generation of hemp
From the hands of Enecta, an Italian-Dutch company, founded in the Netherlands in 2012 and based in Bologna, Italy, Enectarol was born. After more than five years of research to develop a new strain worthy of the name, recent studies conducted in Italy on the Enectarol strain have shown that it produces 5.5% CBG against less than 0.1% THC. The latter is half of the THC limit allowed by EU regulations.
The birth of this new generation of cannabinoid-rich, high-performance European hemp marks a milestone in the evolution of both the company and the hemp industry, according to Enecta's founder, Jacopo Paolini. Moreover, it meets a need for rich hemp flowers that Europe is rather short of.
Indeed, new genetics in the field, which are evolving at a considerable rate, are not represented in the EU's common catalogue, which does not reflect this reality. This is evidenced by the fact that most of the varieties in the catalogue are derivatives of fibre strains.
Consequently, there is a lack of innovative varieties. Jacopo Paolini finally stated that this is a definite disadvantage for the European hemp industry, which will have to overcome this sooner or later.
Quality through expertise and transparency
Enecta has more than ten years of experience in the field of hemp and is used to collaborating with renowned researchers, such as Giesen Research Group (Netherlands) or Becanex (Berlin). In addition to the genetics division, the company also produces and supplies highly concentrated cannabinoid products to the medical, pharmaceutical and nutraceutical industries.
